https://www.live-feeds.com/feed/we-re-raising-our-price-target-on-eli-lilly-as-the-obesity-drug-boom-rolls-onContinuously updated, source-cited coverage. https://www.live-feeds.com/feed/we-re-raising-our-price-target-on-eli-lilly-as-the-obesity-drug-boom-rolls-onhttps://www.live-feeds.com/feed/we-re-raising-our-price-target-on-eli-lilly-as-the-obesity-drug-boom-rolls-on#u167485Sun, 01 Nov 2026 09:52:44 +0000Eli Lilly shares climbed to a record high following a stronger-than-expected earnings report fueled by surging demand for weight-loss and diabetes treatments Zepbound and Mounjaro. The company lifted its full-year revenue outlook due to robust weight-loss drug sales, though it trimmed its profit view to account for deal charges. Strong GLP-1 drug performance also drove another guidance lift as the obesity-drug boom continued to expand across the market. Meanwhile, ServiceNow stock experienced a sharp plunge during the same earnings update cycle.Why it mattersThe pharmaceutical giant benefited